Literature DB >> 1009528

Further experience with isophosphamide.

G Falkson, H C Falkson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1009528

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  10 in total

1.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.

Authors:  P H Willemse; M E vd Burg; A vd Gaast; J P Neijt; W W ten Bokkel Huinink; J G Aalders; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Authors:  C Manegold; P Worst; J Bickel; H Schmid; P Drings; M Kaufmann
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.

Authors:  F Sanchiz; A Milla
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.

Authors:  C I Falkson; H C Falkson; G Falkson
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

7.  Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.

Authors:  G Falkson; M R Chasen; H C Falkson
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 8.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.

Authors:  G Falkson; J J Van Dyk; R Stapelberg; H C Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.

Authors:  G G Steger; C Dittrich; O Schlappack; R Mader; C Herold; W P Brade; A Keller; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.